Crescent Biopharma, Inc.
CBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$13.27
KIRA · Stoqly’s AI analyst, in plain words
- Crescent Biopharma, Inc. had $10.8M of revenue in fiscal 2025. Over five years, revenue changed +1.3% a year on average.
- Its operating margin was −1,407.5%: of every 100 in sales, about −1,408 is left after running the business.
- Crescent Biopharma, Inc. lost $154M in fiscal 2025.
- Free cash flow was −$72.5M in fiscal 2025, −668.1% of revenue.
Market cap
—
P/E
—
Revenue
$10.8M
Net income
−$154M
Free cash flow
−$72.5M
Operating margin
−1,407.5%
Crescent Biopharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−1,419.6%
No. It lost money last year.
Does profit turn into cash?
−668.1%
No. It spent more cash than it brought in.
What Crescent Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- CRESCENT BIOPHARMA, INC.
- CIK
- 0001253689
Crescent Biopharma, Inc. · CBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2M | $0.1M | $0.0M | — | $10.8M |
| Revenue growth | −88.6% | −93.5% | −86.7% | — | — |
| Operating margin | −5,470.5% | −63,204.4% | −392,753.0% | — | −1,407.5% |
| Net income | −$63.4M | −$46.7M | −$36.9M | −$37.9M | −$154M |
| Net margin | −5,468.8% | −62,251.7% | −368,994.0% | — | −1,419.6% |
| Diluted EPS | −$1.23 | −$0.89 | −$0.58 | −$0.59 | — |
| Cash | |||||
| Cash from operations | −$57.5M | −$46.5M | −$34.9M | −$31.1M | −$71.5M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M | $0.9M |
| Free cash flow | −$57.5M | −$46.5M | −$34.9M | −$31.1M | −$72.5M |
| FCF margin | −4,958.1% | −62,055.6% | −349,013.0% | — | −668.1% |
| Share count change | 12.5% | 2.1% | 20.6% | 1.8% | — |
| Debt and strength | |||||
| Cash and short-term investments | $90.3M | $47.9M | $41.8M | $34.8M | $213M |
| Shareholders' equity | $81.6M | $42.9M | $38.4M | −$15.5M | $203M |
| Current ratio | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Interest coverage | — | — | — | — | −69.9x |
| Returns and quality | |||||
| Return on equity | −60.5% | −75.0% | −90.7% | −330.3% | −164.2% |
| Return on tangible equity | −77.7% | −108.8% | −96.1% | — | −65.7% |
| Piotroski F-score | 1 | 1 | 3 | — | — |
| Altman Z'' | −5.2 | −22.2 | −27.5 | −4.9 | 4.6 |
Insiders bought, 12 months
$30.6M
2 insiders
Insiders sold, 12 months
$1.5M
7 insiders
Of sales under plans
100%
$1.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Crescent Biopharma, Inc. · CBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.27 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001253689). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.